Presenting their achievement at the Annual Meeting of the American Society for Virology that took place on July 17th, NanoViricides, Inc. (OTC:NNVC) disclosed some results from the mice testing of their nanoviricides directed to the elimination of the Ebola virus. Results were modest.MT. Dr. Corrine Scully stated, that the in vivo testing demonstrated the nanoviricides were “well tolerated” and “showed some efficacy”. This means the mice didn’t die, but didn’t get well in the process. Some efficacy, though, could mean the variation in dosage would help to achieve better results.
In awe and confusion, traders pushed the stock price down, as more substantial results were expected from the highly potential cure.[BANNER]
New goals have been set in the results – the company is now aiming to treat Ebola and Marburg viruses with the same vaccine. Tests show such a possibility, but the problem has been unsuccessfully addressed by many researchers in the past – a historical remark not to get the hopes too high.
While the scientists behind the developments are just getting excited, investors don’t yet see the potential gains. It will take time to get nanoviricides working, or prove this impossible, and the profit hungry market participants are not eager to wait.
Still, the price shouldn’t get too low as NNVC has secured enough capital to get the operations going till the end of 2011. $0.50-$1.00 per share range should be as low as the long-term debt free company is priced. Short-term rallies are luring in day traders, but as Nanoviricides is still in early development stage, long-term investments bare too much risk.
